SCHEMBL876016

SCHEMBL876016

BC1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17348245 0.94
SCHEMBL2735132 0.84
SCHEMBL22404285 0.84 ADH1A (0.32)
SCHEMBL12658452 0.80 ALDH1A1 (0.36)
SCHEMBL20273253 0.80 ALDH1A1 (0.36)
SCHEMBL23543234 0.80 ALDH1A1 (0.36)
SCHEMBL8290254 0.80 ALDH1A1 (0.36)
SCHEMBL8043535 0.80 ALDH1A1 (0.36)
SCHEMBL15892155 0.80 ALDH1A1 (0.36)
SCHEMBL23104995 0.80 ADH1C (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119775259-B Amatinib intermediate Synthesis method of intermediate 烟台舜康生物科技有限公司 2025-05-13 CN claimed
CN-119775259-A Amatinib intermediate Synthesis method of intermediate 烟台舜康生物科技有限公司 2025-04-08 CN claimed
US-20250163077-A1 MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF INSILICO MEDICINE IP LIMITED (HK) 2025-05-22 US disclosed
CN-119775259-B Amatinib intermediate Synthesis method of intermediate 烟台舜康生物科技有限公司 2025-05-13 CN disclosed
CN-119775259-A Amatinib intermediate Synthesis method of intermediate 烟台舜康生物科技有限公司 2025-04-08 CN disclosed
US-20240226106-A1 INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES (US) 2024-07-11 US disclosed
WO-2024141757-A1 LSD1 MODULATORS EXSCIENTIA AI LIMITED (GB) 2024-07-04 WO disclosed
CN-117886805-A FabI enzyme inhibitor and preparation method and application thereof 广州白云山医药集团股份有限公司白云山制药总厂 2024-04-16 CN disclosed
EP-3712144-B1 P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF BEIJING TIDE PHARMACEUTICAL CO LTD (CN) 2024-02-14 EP disclosed
US-20240025882-A1 BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-01-25 US disclosed
EP-4301752-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF Cambridge Enterprise Limited (GB) 2024-01-10 EP disclosed
US-7410998-B2 Inhibitors of NADH:ubiquinone oxidoreductase THE SCRIPPS RESEARCH INSTITUTE (US) 2008-08-12 US disclosed
WO-2008080120-A2 3-AMINO CHROMANE DERIVATIVES WYETH (US) 2008-07-03 WO disclosed
US-7390825-B1 Process for the preparation of oxazolidinones and method of use thereof BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2008-06-24 US disclosed
US-20080146458-A1 PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2008-06-19 US disclosed
US-7354656-B2 Floor covering made from an environmentally friendly polylactide-based composite formulation MICHIGAN STATE UNIVERSITY, BOARD OF TRUSTEES (US) 2008-04-08 US disclosed
US-20070257023-A1 Heater plate and a method for manufacturing the heater plate WATANABE KATSUMI 2007-11-08 US disclosed
WO-2007056497-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2007-05-18 WO disclosed
WO-2007025144-A1 5-HT2C RECEPTOR AGONISTS AS ANORECTIC AGENTS UNIVERSITY OF ILLINOIS - CHICAGO (US) 2007-03-01 WO disclosed
WO-2004078733-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-09-16 WO disclosed